teroxirone and Lung-Neoplasms

Therapy by targeting cancer stem cells (CSCs) is an eligible method to eradicate malignant human tumors. A synthetic triepoxide derivative, teroxirone, was reported effective against the growth of human lung cancer cells by injuring cellular mitochondria functions. And yet it remains unclear if the residual but malicious CSCs can be effectively dissipated following treatment. The current study further affirmed that teroxirone inhibited the propagation of CSCs as enriched from NSCLC cells by inducing p53 that lead to ultimate apoptosis. More evidence supported that the reduced stemness of the spheroids was associated with apoptotic death. The results consolidate the notion that teroxirone is a viable and effective therapeutic agent for eradicating human lung cancer.

Topics: Apoptosis; Biomarkers, Tumor; Bromodeoxyuridine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Fluorescence; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Neoplastic Stem Cells; Spheroids, Cellular; Triazines; Tumor Stem Cell Assay

Topics: Administration, Oral; Animals; Drug Administration Schedule; Female; Injections, Intraperitoneal; Lethal Dose 50; Leukemia, Experimental; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Triazines